Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:01:53.015Z.
Calculation as of: 2026-10-06T18:01:53.015Z.
Quote observation: 2026-10-06T18:00:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Definium Therapeutics, Inc.
Market Cap
$4.68B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.67B
Price/OCF Ratio
21.44
TTM Avg
18.81
3Y Avg
169.88
5Y Avg
191.97
Market Cap
$4.69B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.66B
Price/OCF Ratio
13.43
TTM Avg
16.00
3Y Avg
16.81
5Y Avg
18.87
Market Cap
$4.72B
Price/OCF Ratio
104.10
TTM Avg
302.47
3Y Avg
302.47
5Y Avg
302.47
Market Cap
$4.80B
Price/OCF Ratio
N/A
TTM Avg
198.10
3Y Avg
199.02
5Y Avg
199.02
Market Cap
$4.44B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.41B
Price/OCF Ratio
N/A
TTM Avg
17.89
3Y Avg
33.70
5Y Avg
30.73
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.68B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.67B | 21.44 | 18.81 | 169.88 | 191.97 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.69B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 13.43 | 16.00 | 16.81 | 18.87 |
| BillionToOne, Inc. (BLLN)vs › | $4.72B | 104.10 | 302.47 | 302.47 | 302.47 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.80B | N/A | 198.10 | 199.02 | 199.02 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.80B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.44B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | N/A | 17.89 | 33.70 | 30.73 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | N/A | 17.21 | 17.21 | 17.21 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
